Presently, over 240 ADC therapy candidates are being evaluated in clinical by roots analysis

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.

• A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of Antibody Drug Conjugates Market (5th Edition), 2019-2030.er, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency.
• Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.
• An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
• A list of key opinion leaders (KOLs) within this domain, featuring detailed 2X2 matrices to assess the relative experience of key individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations and strength of professional network (based on information available on Antibody Drug Conjugates Market (5th Edition), 2019-2030.edIn).

 

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this Antibody Drug Conjugates Market (5th Edition), 2019-2030.

 

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

• Type of Payload
• MMAE
• DM4
• Camptothecin
• DM1
• MMAF
• Others

 

• Type of Antibody Drug Conjugates Market (5th Edition), 2019-2030.er

• VC
• Sulfo-SPDB
• SMCC
• VA
• Hydrazone
• Others

 

• Target Indication

• Breast cancer
• Lymphoma
• Leukemia
• Urothelial cancer
• Lung cancer
• Ovarian cancer
• Others

 

• Target Antigen

• CD30
• HER2
• CD22
• CD33
• Others

 

• Technology Providers

• Seattle Genetics
• ImmunoGen
• StemCentRx
• Immunomedics
• Others

 

• Key Geographical Regions
• North America
• Europe
• Asia Pacific

 

The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

• Bristol Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

1. Market Overview
    

5. Company and Drug Profiles
 

6. Key Therapeutic Areas
 

7. Key Opinion Leaders
 

8. Target Competitiveness Analysis
 

9. Partnerships and Collaborations
 

10. Funding and Investment Analysis
 

11. Patent Analysis
 

12. Academic Grants
 

13. Key Commercialization Strategies

 

14. Promotional Analysis

 

15. Combination Therapies

 

16. Novel Conjugation Technology Platforms

 

17. Assessment of Non-Clinical Data, First in Human Dosing

 

18. Cost Price Analysis

 

19. Case Study: Contract Manufacturing of ADC

 

20. Case Study: Companion Diagnostics for ADC Therapeutic

 

21. Market Forecast and Opportunity Analysis

 

22. Swot Analysis
 

23. Conclusion

 

24. Executive Insights

 

25. Appendix 1: Tabulated Data

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]